Edition:
United Kingdom

ZIOPHARM Oncology Inc (ZIOP.OQ)

ZIOP.OQ on NASDAQ Stock Exchange Capital Market

4.44USD
13 Dec 2017
Change (% chg)

$0.27 (+6.47%)
Prev Close
$4.17
Open
$4.15
Day's High
$4.48
Day's Low
$4.15
Volume
333,763
Avg. Vol
292,646
52-wk High
$7.88
52-wk Low
$3.90

Chart for

About

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies... (more)

Overall

Beta: 1.54
Market Cap(Mil.): $890.11
Shares Outstanding(Mil.): 141.96
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Ziopharm Oncology reports third quarter financial results

* Ziopharm Oncology reports third quarter 2017 financial results and provides update on recent activities

06 Nov 2017

BRIEF-Ziopharm Oncology reports Q2 loss per share $0.13

* Ziopharm Oncology reports second quarter 2017 financial results and provides update on recent activities

31 Jul 2017

BRIEF-Ziopharm Oncology announces initiation of stereotactic treatment cohort in phase 1 study of Ad-RTS-hIL-12 + veledimex in recurrent glioblastoma

* Ziopharm Oncology announces initiation of stereotactic treatment cohort in phase 1 study of Ad-RTS-hIL-12 + veledimex in recurrent glioblastoma

28 Jun 2017

Earnings vs. Estimates